Almac Diagnostic Services We are a precision medicine company specialising in biomarker driven clinical trials. Our global CLIA and CAP accredited laboratories cover UK, Europe, USA and APAC regions. Our cores services: * Multi-Omic Services: We offer a range of genomic & proteomic platform and chemistry options, alongside expert data sciences support & a specialty central lab service. * Clinical Biomarker & CDx Development: Custom Clinical Biomarker & CDx development, validation & delivery service from our CLIA & CAP accredited laboratories in USA, Europe and APAC. * Clinical Testing: Global clinical trial testing service from our clinical laboratories, including a menu of platforms & assays and an integrated specimen collection & logistics service. Find Out More www.almacgroup.com/diagnostics | The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Operating from state-of-the-art facilities in the US, Europe, and the UK, Almac Pharma Services is a FDA, HPRA, and MHRA approved CDMO partnering with global pharmaceutical and biotechnology industries. We have over 50 years’ experience in providing a comprehensive range of tailored solutions. Almac possesses a wealth of technical expertise to support the delivery of your complex projects. Our scientists can develop your clinical candidate into an optimum formulation, and solid manufacture oral dose products for all stages of clinical trials. Almac’s integrated pharmaceutical development solutions are tailored to meet your needs. We specialise in the manufacture & primary packaging of solid, oral dosage forms (Tablets, Capsules and Powders). As well as customised secondary packaging for all drug products including ultra-low temperature drug products. Almac works in close partnership with our clients offering unique solutions designed to support the efficient and successful development, and commercialisation of new treatment options. | Operating from state-of-the-art facilities in the US, Europe, and the UK, Almac Pharma Services is a FDA, HPRA, and MHRA approved CDMO partnering with global pharmaceutical and biotechnology industries. We have over 50 years’ experience in providing a comprehensive range of tailored solutions. Providing end-to-end integrated solutions to bring your drug product from development through to commercialisation from a single source. We work with clients to provide pharmaceutical development, manufacturing, product launch, and packaging solutions to fit their unique needs. Our team of experts can support the development of fit-for-purpose formulation for First-in-Human trials, to developing a more robust formulations scaling up for late phase trials, and ultimately commercialisation. Supporting key development and manufacture areas such as paediatrics, potent and highly potent products. We provide primary and secondary packaging for all drug products including ultra-low temperature drug products and specialised kit assembly. Almac was one of the 1st EU CDMOs to support gene therapy product launches, and currently supports 25% of EU approved/pre-registration Gene Therapy solutions. We provide end-to-end management of drug product supply, including distribution, packaging design, and support initial and ongoing global product launch. We provide unique, tailormade solutions designed to support the efficient and successful development, and commercialisation of new treatment options. Partnering with our clients to provide flexible, stable, ongoing supply to meet their product pipeline needs. | The Almac Group is a global leader in providing a range of expert services and support across the drug development lifecycle. A privately owned organisation, under the McClay Foundation, Almac has grown organically over the past five decades, now employing over 7,500 highly skilled individuals across 18 locations in Europe, the US and Asia. Almac Group is comprised of 5 Business Units: • Almac Diagnostic Services • Almac Sciences • Almac Pharma Services • Almac Clinical Services • Almac Clinical Technologies Each Business Unit offers specialist and dedicated solutions at each phase of the product lifecycle providing the ability to select single or multiple, integrated solutions to meet your unique needs. Our unique combination of inspirational people, exceptional innovation and outstanding quality, enables us to provide tailored solutions for your specific requirements – either on a single, standalone project or on a long-term basis as your strategic partner. About Almac Pharma Services: With over 55 years’ experience, Almac Pharma Services is an established, reliable and world leading outsourcing partner to the global pharmaceutical and biotechnology industry. Employing over 1,800 highly skilled individuals across 4 locations in Europe and the US, we provide a range of tailored, quality-led and timely solutions from early and late phase pharmaceutical development, clinical and commercial drug product manufacture, product launch through to commercial packaging and global distribution. Currently supporting client portfolios across more than 70 countries, our fully integrated, end-to-end solutions are tailored to meet the needs of your unique products, and, ultimately, your patients. Pharmaceutical Development Solutions: Spanning both early and late phase development, our teams of expert scientists possess a wealth of experience in developing clinical candidates into optimal formulations and manufacturing high-quality oral dose products for all phases of clinical trials. Operating both non-GMP and GMP facilities we have complementary equipment trains and integrated technical teams to facilitate technology transfer providing a seamless transition between formulation and process development, and clinical trial material manufacturing. Through a range of flexible and fully tailored unit operations including blending, roller compaction, high shear granulation, encapsulation (including Xcelodose) micro encapsulation and fluid bed processing, we offer the following oral dose formulations with batch sizes ranging from grams to tons: • API / powder in hard gelatin capsules or bottles, including micro-dosing • Formulated blends in hard gelatin capsules or bottles • Tablets (coated) • Mini-tablets • Granules • Beads/pellets • Non-sterile liquid in capsules or bottles • Immediate and modified release • Fixed dose combination products • Potent and highly potent products (OEL as low as 0.05 ug/m3/8 hours) • Specialist paediatric drug development expertise Analytical Solutions: We employ over 700 highly skilled analysts working in state-of-the-art, fully certified GMP laboratories across Europe and the US with significant experience in the analysis of both small and large molecules. We support drug substance (API) and drug product (finished product) analytics across all phases of clinical development through to commercial release. We offer a range of tailored services including: • Method development • Method validation • Method transfer • Stability programmes • Release analysis: all lifecycle stages • Spectroscopy services • Investigational analysis • Reference standard management • Microbiological testing • Physical sciences • Bio-pharmaceutical testing • Analytical support for clinical trial supplies Commercial Manufacture Solutions: Scaling up from our oral dose development assets and expertise through registration and launch into commercial supply, or transferring existing commercial products, we support your commercial manufacturing needs with flexibility and expertise. With blend sizes from 10kgs up to 2.5 tons, our range of state-of-the-art processing equipment is designed to enable scalability to the batch size requirements of your product for a range of presentations including: • Tablets • Mini-tablets • Capsules • Powders • Granules • Beads/pellets • Non-sterile liquids • Potent and highly potent products (OEL as low as 0.05 ug/m3/8 hours) • Specialist paediatric drug manufacturing expertise Commercial Packaging Solutions: Our high and low throughput operations provide the flexibility and efficiency necessary to meet your ongoing and fluctuating demand. Our commercial facilities in Europe and the US, combined with our local expertise offers flexible, quality-led commercial pharmaceutical packaging solutions tailored to meet your specific needs. Our range of primary packaging solutions include: • Tablets • Mini-tablets • Capsules • Powders • Granules • Non-sterile liquid • Our secondary packaging, labelling and assembly capabilities include: • Bottles Vials / ampoules • Pre-filled syringes • Wallets / blister cards • Auto-injectors • Cartons • Sachets • Stick packs • Offline blister printing Innovative, specialist packaging solutions including: • Specialist paediatric drug packaging expertise • Expert cell and gene therapy (ATMP) Ultra Low Temperature (ULT) solutions (-20° to -80°) • Complex medical kit assembly solutions via our unique, custom built semi-automated packaging technology Support Solutions: We provide a wide range of tailored support and consultancy services to help guide you through every aspect of your unique development and commercialisation journey. Find out more – www.almacgroup.com
AINGENS
AINGENS develops fit-for-purpose Al narrative and engagement solutions for the life sciences. Our first product, MACg (Medical Affairs Content Generator), is a complete Al medical writing and research assistant designed to enhance scientific content development workflows. It includes PubMed search, an advanced editor, automated citation management, prebuilt prompts, a flexible reference repository, web search, and ASK MACg, the Al agent. Learn more and start a free trial at https://aingens.com/macg.
Agno Pharma
Agno Pharmaceuticals is a global small molecule CDMO supplying critical regulatory starting materials (RSMs) intermediates, active pharmaceutical ingredients (APIs) and finished dose formulations (oral, injectable & devices). Our capabilities include the manufacturing and handling of highly potent APIs, sterile APIs, water insoluble sterile drug product formulations (spry drying, nanomilling), long acting injectables, drug eluting and implantable devices to biotech, pharmaceutical, generic partners. Our expertise and excellent regulatory track record supports our sponsors from early drug development and process chemistry optimization through to large scale commercial stage cGMP manufacturing. | Your Premier Global End-To-End CDMO Purer Solutions for a Better Life ! Unlocking the potential of pharmaceutical innovation, Agno Pharmaceuticals offers comprehensive solutions spanning from critical API development to sterile drug product formulation to cGMP manufacturing for clinical trials to commercial production of APIs, Chemical Intermediates, Regulatory Starting Materials, and Drug Product. With a track record of excellence and cutting-edge facilities, we specialize in tailored services for clients worldwide, delivering quality solutions for over 20 years. With cutting-edge facilities, seasoned experts, and a commitment to excellence, we provide tailored services across the drug development spectrum, ensuring superior quality and compliance from preclinical to commercialization.
AgonOx, Inc.
Unlocking the Curative Potential of Tumor-Reactive T Cells. AgonOx, Inc. started in 2012 with the primary aim of advancing immunotherapies for cancer. The research strategy at AgonOx focuses on the interaction between T cells and tumor cells. Using bioinformatics, in-vitro, and in-vivo testing to identify and validate new therapeutic approaches. AgonOx conducts its research in laboratories at the Portland Providence Cancer Center where staff scientists work closely with oncologists, surgeons, immunologists, and vivarium staff. Ultimately this collaboration has led to two first-in-human clinical trials with the latest commencing in August 2023. The company’s lead product AGX148 is an adoptive T-cell therapy for treating patients with solid malignancies. | AgonOx, a privately held clinical-stage biotechnology company, is developing novel cancer immunotherapy cell therapeutics. ►The lead T cell therapy program, AGX148, uses patented technology to selectively sort the tumor-reactive T cells from most solid malignancies such as melanoma, H&N cancer, and breast cancer. ►This process can expand cells from as few as 1,000 T cells to as many as 40 billion, which are then used as an autologous cell therapy for patients. ►The manufacturing technique has been quite reproducible for the first 8 patients treated (averaging 25 billion cells/patient infusion) and has shown encouraging clinical results and safety data when treating patients with several types of checkpoint-refractory solid cancers. ►So far, treatment for patients with Melanoma, Thyroid, Ovarian, and Head and Neck cancers has shown promising safety and effectiveness, with tumor shrinkage observed in all 7 patients treated, including partial and complete responses.
Agilex Biolabs
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical and GLP toxicology laboratory, has been delivering bioanalytical services for non-clinical studies and clinical trials for over 28 years. Agilex boasts world-class facilities equipped with cutting-edge equipment, including 17 Sciex API LC-MS/MS mass spectrometers to measure small molecule drugs, including novel chemical entities, nucleotides, enantiomers, peptides. Their immunoassay and immunobiology laboratories feature state-of-the-art equipment for large molecule bioanalysis, such as Gyrolab xPlore, MSD Quickplex 120, BD FACSymphony A3 flow cytometers, and BioRad droplet digital quantitative real-time analysers for RNA, siRNA, and miRNA clinical trials, including vaccines and gene therapy trials. Agilex also offers a range of rodent toxicology, including non-GLP and GLP toxicology services and pharmacokinetics studies, to support preclinical through to early/late-phase clinical programs at its custom-built, state-of-the-art GLP facility in Brisbane, Australia. With expertise in all types of molecules, laboratory species, routes of administration, and non-clinical studies, in addition to multiple certifications such as ISO/IEC17025 accreditation and OECD GLP recognition with NATA, Agilex ensures the highest quality standards for seamless end-to-end testing from preclinical to clinical analysis. As a proud member of the Healius network and through its partnership with global laboratory provider SGS, Agilex Biolabs offers a one-stop-shop package to support multi-region drug development from preclinical to late phase, accelerating hundreds of nonclinical and clinical trials for sponsors from the USA, APAC, and Europe.
AGC Biologics
AGC Biologics is a global CDMO providing pharmaceutical development and manufacturing services for protein-based biologics and cell and gene therapies. With seven facilities and teams of scientists across three continents, we have the resources and the available capacity you need to accelerate your race to GMP. From development, to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the drug development and manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, Messenger RNA (mRNA) and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing, Quality Control and Quality Assurance and Process Validation. We forge exceptionally strong partnerships with our clients and we never lose sight of our commitment to deliver reliable and compliant drug substance. | AGC Biologics is a global CDMO providing pharmaceutical development and manufacturing services for protein-based biologics and cell and gene therapies. With eight facilities and teams of scientists across three continents, we have the resources and the available capacity you need to accelerate your race to GMP. From development, to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the drug development and manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, Messenger RNA (mRNA) and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing, Quality Control and Quality Assurance and Process Validation. We forge exceptionally strong partnerships with our clients and we never lose sight of our commitment to deliver reliable and compliant drug substance. | AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,800 Team Members worldwide. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. | x
ActivInsights
ActivInsights is a Digital Health company. ActivInsights delivers activity, sleep and lifestyle insight to healthcare professionals. We simplify access to real-world patient data with our wearables, connected technologies and secure data infrastructure. With a commitment to improving global public health, ActivInsights is accelerating pharmaceutical drug development, enhancing clinical practice and improving disease management. Our high resolution wearable technologies are designed to be very low burden for long-term continuous wear for participants. We offer a true, unfiltered tri-axial raw data acceleroemeter, the GENEActiv, and a near-real time device, the Activinsights Band for long-term wear. The wearables achieve high compliance and adherence, are cost-effective and enable objective insights into physical activity, gait and mobility, sleep, lifestyle and disease progression. Babies as young as 8 weeks old have worn the devices, up to older adults on the wrist. ActivInsights technologies can be deployed in an array of therapeutic areas to truly understand the patient’s wellbeing in a free living environment, outside of the clinic. We offer seamless integration into existing platforms and can support data processing and analysis services to deliver meaningful digital biomarkers and objective outcome assessments.
Accelsiors Gmbh
Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2025 in the German Pavilion to explore how we can advance your next clinical breakthrough. At Accelsiors CRO, we accelerate biopharmaceutical innovation through a science-driven, patient-centric approach. As a global, full-service CRO, we provide tailored clinical trial solutions designed to de-risk development, optimize timelines, and bring transformative therapies to market faster. With a proven track record in global clinical development, we navigate the complexities of modern drug research—from early-stage clinical development to regulatory approvals and patient-centric trials. Our strategic approach, cutting-edge AI analytics, and deep therapeutic expertise ensure seamless execution and measurable outcomes. | Accelsiors CRO – Science-Driven Clinical Excellence Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2026 in the German Pavilion to explore how we can advance your next clinical breakthrough. Let’s discuss how we can accelerate your next clinical breakthrough with Accelerant™, our proprietary Penta-Helix approach—a unique integration of science, patient-centricity, Quality by Design, AI-driven state-of-the-art technologies, and speed with cost-effectiveness at every stage of clinical development.
ABRACRO
ABRACRO, Brazilian Association of CROs, is a non-profit association that brings together and represents CROs established in Brazil, to contribute to the improvement of the regulatory processes of clinical research in the country and stimulate the development of scientific and educational activities linked to the sector. Founded in 2005, ABRACRO represents foreign and Brazilian CROs operating in the whole country, and brings together other service providers that work with a focus on clinical research, such as logistics and customs companies. The association also aims to ensure the practice of ethics and obedience to the rights of volunteers involved in clinical trials, following the Brazilian and international regulatory standards. It is also the ABRACRO’s mission to support the education and training of clinical research professionals | ABRACRO is a non-profit association that brings together and represents CROs established in Brazil and other companies that act in clinical research, to contribute to the improvement of the regulatory processes of clinical research in the country and stimulate the development of scientific and educational activities linked to the sector. Founded in 2006, ABRACRO represents 35 foreign and Brazilian companies operating in the whole country. The association also aims to ensure the practice of ethics and obedience to the rights of volunteers involved in clinical trials, following the Brazilian and international regulatory standards.
ABIQUIFI – Brazilian Pharmochemical Industry Association
xAbiquifi (The Brazilian Association of the Pharmaceutical Ingredients Industry) and Apex-Brasil (The Brazilian Trade and Investment Promotion Agency) jointly lead the Brazilian Pharma & Health Project, a strategic internationalization initiative for Brazil’s pharmaceutical and pharmaceutical ingredients industries. The project aims to increase the global presence of Brazilian companies across the pharma value chain by fostering exports, technology exchange, foreign investment, and international business development. As part of this effort, Brazil will be represented at the BIO International Convention with the Brazilian Pavilion, a dedicated space showcasing innovative companies from across the country’s life sciences ecosystem. This presence is a key action under the project, designed to generate international business opportunities and strengthen Brazil’s position in the global health market.